Korea Pharma KRX:032300KOSDAQ
한국파마 · Korean news coverage and regulatory filings, organized.
Articles, 24h0
Articles, 7 days1
DART filings, 7 days0
Articles tracked1since Sep 11
In Q2 2026, Korea Pharma reported revenue of ₩25.9bn, up 10.8% year on year, and operating profit of ₩2.2bn. Korea Pharma (한국파마) appeared in 1 Korean news article and 0 DART filings over the past seven days. Coverage peaked on Sep 11 with 1 article.
Korea Pharma quarterly results separate, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩25.9bn | +10.8% | ₩2.2bn | ₩1.3bn |
| Q1 2026 | ₩24.6bn | +18.4% | ₩1.3bn | ₩682m |
| Q4 2025 derived | ₩19.4bn | -11.4% | −₩2.3bn | −₩2.8bn |
| Q3 2025 | ₩24.0bn | +24.8% | ₩507m | −₩21m |
| Q2 2025 | ₩23.4bn | +17.9% | ₩83m | −₩376m |
| Q1 2025 | ₩20.8bn | +2.5% | ₩831m | ₩515m |
| Q4 2024 derived | ₩21.9bn | +7.2% | ₩1.9bn | ₩56m |
| Q3 2024 | ₩19.2bn | -3.0% | ₩1.1bn | ₩1.3bn |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases.
Korea Pharma top stories 2 weeks, by number of outlets
- 1